prevention is very desirable due to its high incidence and impact on healthcare. 5-alpha reductase inhibitors (5ARI) can potentially reduce the risk of PC. A 2010 meta-analysis demonstrated that 5ARI reduced the risks of diagnosis of PC, but could not assess the effect on specific or overall survival. We aimed to update this meta-analysis and most importantly to include data from observational studies on the analysis. Our main objective was to evaluate the impact of 5ARI for PC prevention on specific and overall survival.
INTRODUCTION AND OBJECTIVES: Prostate cancer (PC)
prevention is very desirable due to its high incidence and impact on healthcare. 5-alpha reductase inhibitors (5ARI) can potentially reduce the risk of PC. A 2010 meta-analysis demonstrated that 5ARI reduced the risks of diagnosis of PC, but could not assess the effect on specific or overall survival. We aimed to update this meta-analysis and most importantly to include data from observational studies on the analysis. Our main objective was to evaluate the impact of 5ARI for PC prevention on specific and overall survival.
METHODS: We searched MEDLINE, EMBASE, Cochrane, ClinicalTrials and BVS through April 2018 to identify RCT and observational studies. We included articles with mortality or prostate cancer incidence for men using 5ARI previous to the cancer diagnosis. Each article was assessed independently by two reviewers, both for study selection and data extraction. Summary effects were calculated using Mantel-Haenszel method in a random effects model, and heterogeneity was assessed using I 2 statistics. RESULTS: 3,432 articles were retrieved from the above databases (after exclusion of duplicates). 179 articles were selected for full review, 20 had adequate data for analysis (11 RCT and 9 cohorts). Use of 5ARI had no impact on overall and cancer-specific survival, nor on high-grade prostate cancer diagnosis (attached plots). We identified a reduction in overall cancer diagnosis (16 studies, RR 0.82 95% CI 0.69e0.96, I2 94%). The incidence of low-grade PC diagnosis was not statistically significant (8 studies, RR 0.81 95%CI 0.62e1.06, I2 95%) on the main analysis, but a subgroup considering only RCT identified a substantial reduction in low-grade PC diagnosis (3 studies, RR 0.65 95% CI 0.54-0.79).
CONCLUSIONS: Despite concerns cited by previous studies, we identified no effect on mortality or incidence of high-grade cancers. By reducing overall prostate cancer diagnosis, the use of 5ARI may have an impact on the reduction of PC overdiagnosis and overtreatment.
Source of Funding: None.
MP41-13 TIME FROM BIOCHEMICAL TO CLINICAL RECURRENCE SHOULD BE CONSIDERED AS A PROXY OF OVERALL SURVIVAL IN PATIENTS WITH CLINICALLY-LOCALIZED PROSTATE CANCER WHO EXPERIENCE RECURRENCE AFTER RADICAL PROSTATECTOMY

INTRODUCTION AND OBJECTIVES:
The natural history of surgically treated prostate cancer (PCa) is highly heterogeneous. This is specifically true for individuals experiencing biochemical recurrence (BCR) after radical prostatectomy (RP); not all of these patients would ultimately develop metastases and die from PCa. We sought to investigate the role of time from BCR to clinical recurrence (CR), irrespective of the time from RP, as a surrogate endpoint of overall survival (OS) METHODS: We identified 1,174 patients who underwent RP between 1986 and 2018 at a single center and who subsequently experienced BCR. A Cox model was generated by fitting CR as time-varying covariate. We calculated the time elapsed between BCR and CR. A landmark analysis was performed at 6,12, 36 and 60 mo after the onset of BCR. Multivariable Cox regression analyses assessed the impact of time elapsed between BCR and CR on OS at the landmark points. In this scenario, we considered the occurrence of BCR as the entry point of the analysis. Cox regression models were adjusted for potential confounders including adjuvant therapies. The models' discrimination was assessed with Harrell's c index after internal validation. The added value of time elapsed between BCR and CR to a model for the prediction of OS based on clinical and pathological characteristics was evaluated through the incremental c index and 95%CI RESULTS: Median follow-up survivors was 84 mo. The 5-and 10-yr OS rates were 94% and 86%. In a time-varying model, the occurrence of CR was a predictor of OS (HR 1.14; 95%CI: 1.04-1.26; p[0.007). An interval between BCR and CR of 36 mo was the most informative cut-off for predicting OS (c-index 0.82) vs. 6,12 and 60 mo (c indexes: 0.77,0.78,0.76, respectively) and had an HR of 5.80 (95%CI: 3.17,10.6; p<0.001). Individuals experiencing CR within 36 mo from BCR had a 5-yr OS rate of 40% vs. 95% of the group who progressed to CR later than 36 mo from BCR. A predictive model based on clinical and pathological characteristics and on the administration of adjuvant therapies achieved a c index of 0.74. The incremental c index resulting from the addition of time elapsed between BCR and CR was 0.08 (95%CI:0.06-0.10; p<0.001) CONCLUSIONS: The time elapsed between BCR and CR should be considered as a proxy of OS in PCa patients experiencing recurrence after RP. Patients who progress to CR within 36 mo after BCR are the ones more likely to die from any cause. These individuals should be considered for the administration of salvage therapies and/or novel treatments
Source of Funding: none
MP41-14 TYPE OF PATIENTS IN WHOM BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY CAN BE OBSERVED WITHOUT SALVAGE THERAPY
Kazuhiro Matsumoto*, Naoya Niwa, Masayuki Hagiwara, Takeo Kosaka, Nobuyuki Tanaka, Toshikazu Takeda, Shinya Morita, Ryuichi Mizuno, Toshiaki Shinojima, Tokyo, Japan; Satoshi Hara, Kawasaki, Japan; Eiji Kikuchi, Hiroshi Asanuma, Mototsugu Oya, Tokyo, Japan INTRODUCTION AND OBJECTIVES: We previously reported that salvage therapy for biochemical recurrence (BCR) should be started early, especially for patients with a Gleason score !8 and PSAdoubling time (DT) <6 months because there is a significant risk of subsequent development of castration-resistant prostate cancer (CRPC) against delayed hormonal therapy. Conversely, observation after BCR without salvage therapy or delayed administration are often performed for elderly patients in clinical practice. However, the safety of observation after BCR has not been elucidated. In this study, we examined the prognosis after BCR with and without salvage therapy.
METHODS: The study population consisted of 431 patients, all of whom underwent radical prostatectomy during the period of 1991-2011 and developed BCR (PSA >0.2 ng/mL) after the nadir PSA (<0.2 ng/mL). According to the two risk factors (Gleason score !8 and PSA-DT <6 months), we divided the patients into 2 groups. The high/ intermediate risk group consisted of patients with both or one risk factor. On the other hand, patients with neither factor were in the low risk group. We set the starting point at the timing of BCR, and the endpoints were CRPC and cancer-specific death.
RESULTS: During the mean follow-up period of 8.3 years, development to CRPC was observed in 49 patients (11.4%), and 21 patients (4.9%) died due to prostate cancer. At first, we divided the 191 high/intermediate-risk patients according to the PSA level (PSA <1.0 ng/mL, PSA 1.0-4.0, and PSA >4.0 or no therapy) at the initiation of salvage therapy, including radiation and/or androgen deprivation. We found that delayed (PSA >0.4 ng/mL) or no salvage therapy was significantly associated with castration resistance (Figure 1a ) and cancer-specific death (Figure 1b) . In the 240 low-risk patients, Kaplan-Meier curves demonstrated no significant difference in CRPC-free survival (Figure 1c ) or cancer-specific survival (Figure 1d ) within 10 years from the timing of BCR.
CONCLUSIONS: Our study suggested that observation after BCR without salvage therapy or delayed administration is an option for low-risk patients with a Gleason score 7 and PSA-DT !6 months when their life expectancy is within 10 years. However, for other patients, early salvage therapy against BCR may be advantageous for both CRPC-free and cancer-specific survival.
Source of Funding: none
MP41-15 ASSOCIATION BETWEEN CONTINUITY OF CARE AND SHORT AND LONG-TERM OUTCOMES IN ADVANCED PROSTATE CANCER PATIENTS
Ravishankar Jayadevappa*, S. Bruce Malkowicz, Thomas Guzzo, Sumedha Chhatre, Alan Wein, Philadelphia, PA INTRODUCTION AND OBJECTIVES: Assessment of continuity of care (COC) is important for evaluating the quality of care. In this study, we analyzed the contribution of continuity of care to the association between race and ethnicity and short and long-term outcomes among men with advanced prostate cancer.
METHODS: This was a population-based cohort study. The Surveillance, Epidemiological, and End Results-Medicare (SEERMedicare) data from 2000e2013 was linked with AMA and AHA data. Eligible patients were men 66 years or older with advanced prostate cancer at diagnosis between 2000 and 2003. Continuity of Care index (COCI) was the main independent variable and was computed as the dispersion of visits with different providers as a proportion of total number of visits. The COCI ranges between zero and one, higher COCI indicates higher continuity of care. Short-term outcomes were emergency room (ER) admissions, hospitalization, and cost of care in the two-year period after diagnosis. Long-term outcomes were tenyear mortality (all cause, and prostate-cancer specific). We used Cox regression to model survival, log-link GLM models for cost, and Poisson (zero inflated) models for count data. We evaluated the change in the association between race and ethnicity variable and outcomes explained by the COC index. Propensity score and instrumental variable approaches were used to minimize potential biases.
